Literature DB >> 8217782

The immunocytochemical localization of tumour necrosis factor and leukotriene in the rat kidney after treatment with lipopolysaccharide.

T Kita1, N Tanaka, T Nagano.   

Abstract

Abundant inflammatory cells such as polymorphonuclear leucocytes and macrophages accumulated and adhered to the endothelial surface of glomerular and intertubular veins and capillaries in rat kidneys after administration of bacterial lipopolysaccharide (LPS). There was also damage to both endothelial cells and proximal tubular cells, including intracytoplasmic oedema, and an increase in the number of lysosomes in the proximal tubular cells in the LPS-treated samples. Immunocytochemistry was used to demonstrate tumour necrosis factor (TNF) and leukotriene (LTR) in both LPS-treated and control samples. Immunoreactive LTR seen in the lysosomes of inflammatory cells attached to the endothelial cell surface may indicate the onset of endothelial cell damage. Positive immunoreactive TNF and LTR were seen on the endothelial cell surface only in the LPS-treated samples, indicating that TNF and LTR may enhance the adhesion of leucocytes to endothelium. Positive reactions of TNF and LTR in lysosomes of the mesangial cells suggest that lysosomes of such cells may be involved in the synthesis and storage of TNF and LTR. In addition to these reaction sites, lysosomes of proximal tubular cells were immunoreactive for LTR. These endogenous LTRs may be implicated in the degeneration of the proximal tubular cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217782      PMCID: PMC2002180     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  29 in total

1.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.

Authors:  K C Sheehan; N H Ruddle; R D Schreiber
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

2.  Effect of leukotriene receptor antagonists on vascular permeability during endotoxic shock.

Authors:  J A Cook; E J Li; K M Spicer; W C Wise; P V Halushka
Journal:  Circ Shock       Date:  1990-11

3.  Postischemic renal injury is mediated by neutrophils and leukotrienes.

Authors:  J M Klausner; I S Paterson; G Goldman; L Kobzik; C Rodzen; R Lawrence; C R Valeri; D Shepro; H B Hechtman
Journal:  Am J Physiol       Date:  1989-05

4.  Production of platelet-derived growth factorlike protein by rat mesangial cells in culture.

Authors:  H E Abboud; E Poptic; P DiCorleto
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

5.  Escherichia coli endotoxin injections potentiate experimental ischemic renal injury.

Authors:  R A Zager
Journal:  Am J Physiol       Date:  1986-12

6.  Tissue factor production by cultured rat mesangial cells. Stimulation by TNF alpha and lipopolysaccharide.

Authors:  R C Wiggins; N Njoku; J R Sedor
Journal:  Kidney Int       Date:  1990-05       Impact factor: 10.612

7.  An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism.

Authors:  T H Pohlman; K A Stanness; P G Beatty; H D Ochs; J M Harlan
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

8.  Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo.

Authors:  M Rampart; T J Williams
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

9.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells.

Authors:  M Tsujimoto; Y K Yip; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Species difference in increased vascular permeability by synthetic leukotriene C4 and D4.

Authors:  A Ueno; K Tanaka; M Katori; M Hayashi; Y Arai
Journal:  Prostaglandins       Date:  1981-04
View more
  8 in total

Review 1.  Involvement of tumor necrosis factor-alpha in glomerular injury.

Authors:  L Baud; B Fouqueray; C Philipp
Journal:  Springer Semin Immunopathol       Date:  1994

2.  Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.

Authors:  S J De Kimpe; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  The immunocytochemical localization of tumour necrosis factor and leukotriene in the rat heart and lung during endotoxin shock.

Authors:  N Tanaka; T Kita; K Kasai; T Nagano
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia.

Authors:  K K Donnahoo; X Meng; L Ao; A Ayala; B D Shames; M P Cain; A H Harken; D R Meldrum
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

Review 5.  Tumor necrosis factor-α: regulation of renal function and blood pressure.

Authors:  Vanesa D Ramseyer; Jeffrey L Garvin
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-20

6.  Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.

Authors:  S Kapadia; J Lee; G Torre-Amione; H H Birdsall; T S Ma; D L Mann
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia.

Authors:  Kamlesh K Gupta; Deborah L Donahue; Mayra J Sandoval-Cooper; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

8.  Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity.

Authors:  Prodyot K Chatterjee; Michael M Yeboah; Oonagh Dowling; Xiangying Xue; Saul R Powell; Yousef Al-Abed; Christine N Metz
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.